Biogen (BIIB) Tops Q4 EPS by 38c, Beats on Revenue; Offers FY26 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biogen earnings preview Q4: set for weaker print, Leqembi outlook in focus
February 6, 2026 2:00 AM ESTInvesting.com-- Biogen is set to report a drop in fourth quarter earnings before the market open on February 6 on weaker sales in its multiple sclerosis drugs, although focus will be squarely on the companys pipeline, specifically its Alzheimers treatment Leqembi.
Biogen is expected to post earnings per share of $1.61 on revenue of $2.21 billion for the three months to December 31, Investing.com forecasts showed. This compares to EPS of $3.44 and revenue of $2.45 billion... More
